Proprietary alpha-amylase inhibitor formulation from white kidney bean (Phaseolus vulgaris L.) promotes weight and fat loss: a 12-week, double-blind, placebo-controlled, randomized trial

Sci Rep. 2024 Jun 3;14(1):12685. doi: 10.1038/s41598-024-63443-8.

Abstract

White kidney bean (Phaseolus vulgaris L.) extracts can aid weight management by reducing calorie intake from complex carbohydrates through alpha-amylase inhibition. We examined the impact of a proprietary aqueous extract from whole dried white kidney beans standardized by its alpha-amylase inhibitor activity (Phase 2 white kidney bean extract (WKBE)) on weight management in subjects with overweight and moderate obesity. In a randomized, double-blind, placebo-controlled fashion, 81 participants completed the study and ingested either a high dose of Phase 2 (1000 mg, WKBE HIGH), a low dose (700 mg, WKBE LOW), or a matching placebo (microcrystalline cellulose, PLA) three times a day, 30 min before meals, for 12 weeks during a calorie restricted diet. In a dose-dependent manner, Phase 2 significantly reduced body weight, fat mass, BMI, waist, hip and in the WKBE HIGH group thigh circumference. Phase 2 is an effective and safe supplement aiding weight and fat loss. ClinicalTrials.gov identifier NCT02930668.

Keywords: BMI; Body shaping; Fat mass; Obesity; Weight management.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Double-Blind Method
  • Female
  • Humans
  • Male
  • Middle Aged
  • Obesity / drug therapy
  • Overweight / drug therapy
  • Phaseolus* / chemistry
  • Plant Extracts* / chemistry
  • Plant Extracts* / pharmacology
  • Plant Lectins
  • Weight Loss / drug effects
  • alpha-Amylases / antagonists & inhibitors
  • alpha-Amylases / metabolism

Substances

  • Plant Extracts
  • alpha-amylase inhibitor, Phaseolus vulgaris
  • alpha-Amylases
  • Plant Lectins

Associated data

  • ClinicalTrials.gov/NCT02930668